Overview

This trial has been completed.

Condition pancreatic adenocarcinoma
Treatment nanoknife low energy direct current (ledc) system ablation
Phase phase 2
Sponsor Angiodynamics, Inc.
Start date May 2011
End date December 2011
Trial size 10 participants
Trial identifier NCT01369420, ONC-208

Summary

The purpose of this study is to evaluate the safety and feasibility of the NanoKnife Low Energy Direct Current (LEDC) System when used to treat unresectable pancreatic adenocarcinoma. Safety will be reviewed by means of analysis of adverse events, including serious adverse events, laboratory data, physician exam findings, and vital signs.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety study
Intervention model single group assignment
Masking open label
Primary purpose treatment

Primary Outcomes

Measure
Safety
time frame: 90 days

Secondary Outcomes

Measure
Efficacy
time frame: 90 days

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: 1. male or female 2. >/= 18 years of age 3. meets criteria for locally advanced unresectable pancreatic adenocarcinoma, as radiographically proven pancreatic cancer as determined by a surgical oncologist via pancreatic CT or who were initially thought to be resectable; however at the time of surgery were upstaged to unresectability, via direct visualization 4. tumor size must be < 4 cm and must be measurable 5. must have an INR <1.5 6. must be unresponsive to chemotherapy as demonstrated with either CT or MR imaging and not have taken any chemotherapy agents within 14 days of treatment with the NanoKnife LEDC System 7. are willing and able to comply with the protocol requirements 8. are able to comprehend and willing to sign an Informed Consent Form (ICF) Exclusion Criteria: 1. a baseline creatinine reported as > 2.0 mg/dL 2. have any reported baseline lab values with a grade 3 or 4 toxicity as defined by the CTCAE Version 3.0 3. inability to stop antiplatelet and Coumadin therapy for 7 days prior to and 7 days post treatment with the NanoKnife System 4. known history of contrast allergy that cannot be medically managed 5. known hypersensitivity to the metal in the electrodes (stainless steel 304L) that cannot be medically managed 6. unable to be treated with a muscle blockade agent (e.g. pancuronium bromide, atracurium, cisatracurium, etc) 7. women who are pregnant or currently breast feeding 8. women of childbearing potential who are not utilizing an acceptable method of contraception 9. have taken an investigational agent within 30 days of visit 1 10. have implanted cardiac pacemakers or defibrillators 11. have implanted electronic devices or implants with metal parts in the immediate vicinity of a lesion 12. have a history of epilepsy or cardiac arrhythmia (atrial or ventricular fibrillation) 13. have a recent history of myocardial infarction (within the past 2 months) 14. have Q-T intervals greater than 550 ms unless treated with an Accysync Model 72 synchronization system controlling the NanoKnife system's output pulses.

Additional Information

Official title A Safety Evaluation of the NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer - A Pilot Study
Principal investigator Claudio Bassi, M.D.
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by Angiodynamics, Inc..